期刊文献+

人Endostatin基因的克隆及其在Hela细胞中的表达

Cloning of Human Endostatin and Its Expression in Hela Cells
下载PDF
导出
摘要 利用RT-PCR克隆人Endostatin基因,分别构建到双顺反子表达载体pIRES2-EGFP和融合表达载体pEGFP-C1中.两个重组表达载体利用脂质体介导转染真核细胞Hela,48 h后可在荧光显微镜下观察到被转染细胞发出绿色荧光.传代10次后,绿色荧光仍持续表达,说明是稳定转染.以转染细胞的总DNA为模板PCR检测Endostatin基因已整合到细胞染色体上.利用兔抗人Endostatin抗体对已转染细胞进行免疫组化检测,显微镜下观察,转染的细胞显棕红色,表明Endostatin在转染细胞内稳定表达.本试验通过报告基因检测,DNA检测,免疫细胞化学检测三个水平证明Endostatin已整合到细胞的染色体上,为基因治疗以及联合治疗打下基础. Human Endostatin cloned by RT-PCR was inserted into bicistronic expression vector pIRES2-EGFP and fusion expression vector pEGFP-Cl,which were transfected into Hela cells with lipofectamine TM regent. After 48 hours,under the fluorescence microscope,the green fluorescence was spreading in the transfected Hela cell. After culturing ten generations, the green fluorescence expressed persistently, which illustrated that the transfection was steady. On the level of total DNA,it can show that Endostatin integrated into total DNA by PCR of transfected Hela cell total DNA. Furthermore,after immunocytochemistry in the fixed tranfected Hela cell with rabbit anti- Endostatin, under the microscope, the transfected Hela cell became brown-red and the negative control was unstained,which meant that Endostatin has expressed in the transfected Hela cell. This experiment advantages gene therapy and therapeutic alliance.
出处 《内蒙古大学学报(自然科学版)》 CAS CSCD 北大核心 2007年第4期413-418,共6页 Journal of Inner Mongolia University:Natural Science Edition
基金 内蒙古自然科学基金项目(重点:200607010502)
关键词 ENDOSTATIN RT—PCR 脂质体转染 免疫细胞化学 HELA Endostatin RT-PCR transfection with lipofectamine immunocytochemistry Hela
  • 相关文献

参考文献13

  • 1Folkman J.Fighting cancer by attacking its blood supply[J].Sei Am,1996,275(3):150-154.
  • 2O'Reilly MS,Boehm T,Shing Y,et al.Endostatin:An Endosgenous Inhibitor of Angiogenesis and Tum or Growth[J].Cell,1997,88:277-285.
  • 3徐根兴,任敏东,许琳.一种人实体瘤血管内皮细胞增殖抑制因子在血管再生治疗中的应用[P].中国专利:117705,1998-03-25.
  • 4Dhanabal M,Ramchandran R,Waterman MJ,et al.Endostatin induces endothelial cell apoptosis[J].J Biol Chem,1999,274(17),11 721-11 726.
  • 5Rehn M,Veikkola T,Kukk Valdre E,et al.Interaction of Endostatin with integrins implicated in angiogenesis[J].Proc Natl Acad Sci USA,2001,98(3):1 024-1 029.
  • 6Shichiri M,Hirata Y.Antiangiogenesis signals by Endostatin[J].FASEB J,2001,15(6):1 044-1 053.
  • 7MacDonald NJ,Shivers WY,Narum DL,et al.Endostatin binds tropomyosin:A potential modulator of the antitumor activity of Endostatin[J].J Biol Chem,2001,276(27):25 190-25 196.
  • 8Hanai J,Dhanabal M,Karumanchi SA,et al.Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1[J].J Biol Chem,2002,277(19):16 464-16 469.
  • 9王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:625
  • 10Xu Han-Mei,Zhang Guo-Yuan,Ji Xiao-Dan.Expression of soluble,biologically active recombinant human endostatin in Escherichia coli[J].Protein Expression and Purification,2005,41:252-258.

二级参考文献31

  • 1杨林,王金万,汤仲明,刘秀文,黄镜,李树婷,董英,张和平,薛岚,储大同,孙燕.重组人血管内皮抑制素Ⅰ期临床研究[J].中国新药杂志,2004,13(6):548-553. 被引量:154
  • 2周清华,孙燕.加强我国肺癌分子靶向治疗基础和临床研究[J].中国肺癌杂志,2004,7(4):267-269. 被引量:51
  • 3杨林,王金万,崔成旭,黄镜,张和平,李树亭,孙燕.重组人血管内皮抑制素YH-16联合用药治疗晚期非小细胞肺癌的多中心Ⅱ期临床试验[J].中国新药杂志,2005,14(2):204-207. 被引量:116
  • 4Folkman J. Role of angiogenesis in tumor growth and metastasis.Semin Oncol,2002,29(6 Suppl 16) : 15-18.
  • 5Huang X, Wong MK, Zhao Q, et al. Soluble recombinant endostatinpurified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res,2001,61(2): 478-481. Erratum in:Cancer Res, 2001,61 ( 15 ) : 5956. Cancer Res, 2001,61 (10) :4297.
  • 6Li B, Wu XY, Zhou H, et al. Acid-induced unfolding mechanism of recombinant human endostatin. Biochemistry, 2004, 43 (9) :2550-2557.
  • 7Eder JP Jr, Supko JG, Clark JW, et al. Phase Ⅰ clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol, 2002,20(18) : 3772-3784.
  • 8Kulke M, Bergsland E, Ryan DP, et al. A phase Ⅱ , open-label,safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc ASCO,2003,22: 958a.
  • 9Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced nonsmall cell lung cancer. J Clin Oncol,2002,20(21) : 4285-4291.
  • 10Gebbia V, Galetta D, Caruso M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine fol lowed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage Ⅲ B-Ⅳ non small cell lung carcinoma: a prospective randomized phase Ⅲ trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer,2003,39(2) :179-189.

共引文献624

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部